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Abstract 
Background: The pharmaceutical industry is in the midst of a productivity crisis and rates of translation from bench 
to bedside are dismal. Patients are being let down by the current system of drug discovery; of the several 1000 dis‑
eases that affect humans, only a minority have any approved treatments and many of these cause adverse reactions 
in humans. A predominant reason for the poor rate of translation from bench to bedside is generally held to be the 
failure of preclinical animal models to predict clinical efficacy and safety. Attempts to explain this failure have focused 
on problems of internal validity in preclinical animal studies (e.g. poor study design, lack of measures to control bias). 
However there has been less discussion of another key factor that influences translation, namely the external validity 
of preclinical animal models.
Review of problems of external validity: External validity is the extent to which research findings derived in 
one setting, population or species can be reliably applied to other settings, populations and species. This paper 
argues that the reliable translation of findings from animals to humans will only occur if preclinical animal stud‑
ies are both internally and externally valid. We review several key aspects that impact external validity in preclinical 
animal research, including unrepresentative animal samples, the inability of animal models to mimic the complexity 
of human conditions, the poor applicability of animal models to clinical settings and animal–human species differ‑
ences. We suggest that while some problems of external validity can be overcome by improving animal models, the 
problem of species differences can never be overcome and will always undermine external validity and the reliable 
translation of preclinical findings to humans.
Conclusion: We conclude that preclinical animal models can never be fully valid due to the uncertainties introduced 
by species differences. We suggest that even if the next several decades were spent improving the internal and exter‑
nal validity of animal models, the clinical relevance of those models would, in the end, only improve to some extent. 
This is because species differences would continue to make extrapolation from animals to humans unreliable. We 
suggest that to improve clinical translation and ultimately benefit patients, research should focus instead on human‑
relevant research methods and technologies.
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Introduction
Few would dispute that the pharmaceutical industry is 
in the midst of a productivity crisis [1–7] or that rates of 
translation from bench to bedside are dismal [8–15]. Simi-
larly, few would disagree that patients are being let down 
by the current system of drug discovery. Evidence suggests 
that current levels of investment in pharmaceutical drugs 
are out of proportion to their impact in terms of value for 
money or population health [16]. There is not a drug for 
every disease; several thousand diseases affect humans, of 
which only about 500 are estimated to have any approved 
treatments [17]. Many of the treatments that do exist cause 
dangerous and undesirable reactions in humans [18]. This 
failure of the drug discovery system not only lets down 
patients but also uses an enormous amount of resources 
that could likely be better spent [19]. The failure of the cur-
rent drug discovery model is an issue of global importance 
for human health. However, the first step towards resolv-
ing this issue is to identify what is going wrong.
While many factors contribute to the poor rates of 
translation from bench to bedside (including flawed clini-
cal trials [20]), a predominant reason is generally held to 
be the failure of preclinical animal models to predict clin-
ical efficacy [4, 6, 9, 14, 21] and safety [22, 23]. Efficacy 
and safety issues account for the majority of failures (52% 
and 24% respectively) at Phases II and III of clinical trials 
[24]. Attempts to explain these failures have focused on 
problems of internal validity in preclinical animal studies 
(i.e. shortcomings in study design, conduct, analysis and 
reporting), but there has been relatively little discussion 
of another key factor that influences translation, namely 
the external validity of preclinical animal models [25]. 
External validity  is usually taken to mean the extent to 
which research findings derived in one setting, popula-
tion or species can be reliably applied to other settings, 
populations and species [26]. It is a key criterion for 
assessing the credibility of scientific research. In the field 
of preclinical animal research, where the findings derived 
from animal studies are intended to have relevance in 
clinical settings, external validity is of the utmost impor-
tance. External validity is sometimes referred to as gen-
eralisability. Although the two terms are interchangeable, 
we use the term external validity here because general-
isability, despite having a distinct methodological mean-
ing, is often confused with translatability. In fact the two 
concepts are discrete; external validity/generalisability 
contributes to translatability [26] and in fact, as we shall 
argue, it is a prerequisite for the translation of findings 
from animals to humans.
In this paper we argue that the translation of findings 
from animals to humans can only occur reliably if preclini-
cal animal studies are both internally and externally valid. 
We consider the relationship between internal and external 
validity before going on to explore several key aspects that 
impact external validity in preclinical animal research. We 
suggest that while some problems of external validity are 
surmountable, the issue of human–animal species differ-
ences is not; species differences will always have an impact 
on external validity and the ability to translate preclinical 
findings to humans. We explore the implications of this 
conclusion.
The relationship between internal and external 
validity
External validity is distinct from internal validity, which 
refers to the scientific robustness of a study’s design, con-
duct, analysis and reporting. Systematic review evidence 
has revealed that preclinical animal studies suffer from 
serious problems of internal validity, in particular a failure 
to take measures to prevent bias, such as random allocation 
to groups and blinded assessment of outcomes [27–29]. If a 
study does not take such measures then its internal validity 
is poor and its findings cannot be relied upon. Studies that 
lack internal validity will always lack external validity [30]. 
For example, in the field of stroke, animal studies that were 
‘unblinded’ overestimated the effect of the intervention by 
13% compared with studies that included blinding [31]. In 
other words, the lack of blinding led to the benefits of the 
animal studies being overstated. Because the benefits were 
not real, they could not be applied to other populations and 
settings. As such, lack of internal validity led to a lack of 
external validity.
Some believe that if issues of internal validity were 
resolved (i.e. if researchers took measures to prevent bias 
and conducted studies according to agreed scientific stand-
ards) then the clinical translation of animal studies would 
be more successful [32]. However the available evidence 
does not support this view. In 1999 the Stroke Treat-
ment Academic Industry Roundtable introduced a series 
of recommendations and standards intended to improve 
the quality of animal studies in stroke. Yet by 2012 trans-
lation rates had not improved [33] and the situation is no 
better today. Well over a thousand drugs have been tested 
in animal studies of stroke [15] but of these only one has 
translated into clinical use and the benefits of that one 
are controversial [34]. This may be partly because internal 
validity remains poor but it is also due to the fact that pre-
clinical animal studies need to be both internally and exter-
nally valid if they are to translate into benefits for humans 
(see Fig. 1) [10].
Aspects of external validity to consider 
in preclinical animal research
There are several aspects of external validity that raise 
problems within preclinical animal research. Some of 
these are potentially surmountable but others are more 
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intractable. We begin this section by reflecting on the 
surmountable problems of external validity before going 
on to consider a problem of external validity that we 
regard as insurmountable, namely species differences. 
We argue that even if the following surmountable issues 
of external validity were resolved, the issue of species dif-
ferences would continue to undermine external validity 
and therefore clinical translation.
Surmountable problems of external validity
The unrepresentativeness of animal samples is a prob-
lem in preclinical research. In general the standardisation 
of laboratory animal populations produces homogenous 
samples that do not extrapolate to heterogeneous human 
populations [26, 35]. In addition, laboratory animals may 
be housed in conditions that complicate the extrapolation 
of findings to humans. For example the biology of labora-
tory mice may be affected by their being housed in same-
sex groups, by lack of opportunities for physical exercise, 
and by temperature [36] and diet [37]. Furthermore, the 
animals used in preclinical research tend to be young and 
healthy whereas many human diseases manifest in older 
age. For example, animal studies of osteoarthritis (OA) 
tend to use young animals of normal weight, whereas clini-
cal trials focus mainly on older people with obesity [38]. 
Animals used in stroke studies have tended to be young 
whereas human stroke is largely a disease of the elderly 
[39]. It is not hard to see that in such cases the findings 
from animal studies are unlikely to be applicable to human 
patient populations, i.e. they will lack external validity.
Furthermore, many animal models lack the complex-
ity required to accurately mimic human conditions. 
Although there has been some success with diseases 
based on single gene defects that can be reproduced in 
animal models [16], most human diseases tend to evolve 
over time as part of the human life course. For example, 
it may be possible to grow a breast tumour on a mouse 
model but this does not actually represent the human 
experience because most human breast cancer occurs 
post-menopausally. While some animal species may be 
better models of specific diseases than others (e.g. horses 
have similar cartilage degenerative processes as humans 
[40]), in general the animal models currently used do not 
mimic the slow, progressive and degenerative nature of 
many human chronic diseases [10], nor do they involve 
the complexity of comorbidity or polypharmacy (human 
patients often take more than one type of medication). To 
take the example of stroke again, many people with this 
disease have hypertension but preclinical animal stud-
ies of stroke have generally used healthy animals without 
comorbidities, which results in the effects of interven-
tions being overestimated [31]. In fact many experimen-
tal treatments for stroke are less effective in humans with 
hypertension [39]. Furthermore, recovery from a severe 
stroke can take years for humans but animals can recover 
from experimental stroke within days or weeks [41]. 
Additionally, while human stroke is highly heterogeneous 
the four most commonly used stroke animal models are 
all of ischaemic stroke [41].
Finally, animal models developed in the laboratory lack 
applicability to ‘real life’ clinical settings. To return to the 
example of OA, animals are usually given drugs for OA 
prophylactically, or in the early stages of OA, whereas in 
clinical trials humans are usually given drugs in the late 
stages of their disease [38]. Similarly, experimental drugs 
Internal 
validity is poor 
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No translaon 
Internal 
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good 
External 
validity is poor No translaon 
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Fig. 1 The relationship between internal validity, external validity and translation
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for multiple sclerosis (MS) are most commonly adminis-
tered to animals some days before neurological impair-
ment. As these drugs may work by blocking the induction 
of the disease they are not relevant to the human condi-
tion because human patients cannot be identified prior 
to the onset of their MS. Animal models of MS can only 
have clinical relevance if treatment is successfully started 
after the onset of symptoms [42]. Animal models of Par-
kinson’s disease pose a similar problem [43], as do those 
of inflammatory bowel disease [44]. Again, in the case of 
stroke, Tirilazad was able to successfully treat animals if 
given within 10 min of stroke induction but humans are 
highly unlikely to be able to access treatment for stroke 
within 10 min. In clinical trials humans were given Tirila-
zad within a more realistic 5 h and the trials were unsuc-
cessful [39]. The choice of animal models across a range 
of fields appears to lack rationality in terms of evidence-
base or appropriateness in relation to the relevant human 
condition [40, 44].
These failures of animal models to accurately repre-
sent human diseases and clinical contexts are sometimes 
described as failures of construct validity, which is gen-
erally understood to be a subset of external validity [10, 
45]. As noted above, these failures, which may be in part 
due to academic pressures to produce quick, high impact 
papers [46] can potentially be resolved, although some 
of the solutions raise serious ethical issues (e.g. animal 
models that involve ageing and comorbidity are likely to 
be more externally valid but because the harms to ani-
mals are protracted they are more likely to be consid-
ered severe). Yet even if all the surmountable problems 
of external validity described above were resolved, one 
intractable problem would remain. Species differences, 
i.e. the differences between animals and humans in terms 
of their underlying biology, would continue to undermine 
external validity.
The insurmountable problem of external validity: species 
differences
Perlman [36, 47], an evolutionary biologist, points out 
that mice (the most frequently used animals in research) 
and humans have a high level of genetic homology as 
well as many biochemical and physiological similarities. 
He notes however, that the lineages that led to modern 
rodents and primates diverged around 85 million years 
ago and that since then, the species in these lineages 
have become adapted to very different environments. As 
a result, mice and humans now have very different life 
histories, they eat different diets, have different levels of 
physical activity, are exposed to different environmen-
tal toxins and pathogens and have different microbi-
omes. Because they harbour different sets of pathogens 
and microbiomes, host–pathogen and host–microbiome 
coevolution has led to evolved differences between 
the human and mouse immune systems [36, 47]. Fur-
thermore, Perlman [36] suggests that due to different 
network architectures between mice and humans and 
different genotype–phenotype relationships, the relation-
ships between genotype and disease are likely to differ 
in these two species. Critically Perlman notes that while 
mice and other animals may be useful for understanding 
processes that arose early in evolution and that humans 
share with other species, they are less likely to be useful 
for understanding chronic non-communicable diseases 
because the pathogenesis of these diseases is enmeshed 
in our unique, evolved life histories [36, 47, 48].
Nevertheless there is a strong assumption among the 
biomedical community that gene functions and devel-
opmental systems are conserved between animals and 
humans [49]. Moreover, there appears to be little inter-
est within the biomedical community in verifying this 
assumption, or in the evidence emerging from evolution-
ary developmental biology indicating that gene func-
tions and gene networks diverge through evolution [50]. 
Commentators have observed that the animal model par-
adigm tends to discourage any critical appraisal of spe-
cies differences, encouraging instead a view that animal 
based findings are generally applicable to humans [50, 
51] and emphasising the commonalities rather than the 
differences [21]. Preuss [50] suggests that if species dif-
ferences are acknowledged they tend to be ‘soft-peddled’ 
or treated as ‘noise’, again noting that researchers focus 
on ‘commonalities’ and ‘basic uniformity’ instead. But as 
Perlman [36] notes, biology is characterized by diversity 
as well as unity; evolution is ‘descent with modification’ 
[52].
Unfortunately, focusing on the commonalities without 
acknowledging difference is problematic. Sjoberg [53] 
argues that crude inferences are made about the proper-
ties of one group (humans) based on observations from 
another group (animals), simply because both groups 
have some other property in common (genetic similar-
ity). Sjoberg uses the example of Jack and Jill: if Jack is 
clumsy then it might be inferred that his sibling Jill is also 
clumsy. However there is no evidence that Jill is clumsy 
and the argument is based solely on the observation that 
Jack and Jill have genetic properties in common. This 
reasoning, which relies purely on an assumption of simi-
larity (rather than its empirical demonstration), under-
pins the use of animals as models of human disease. As 
Wall and Shani [21] note, the assumption is that if two 
systems are homologous then they are likely to function 
similarly. However this is incorrect; while some molecu-
lar pathways may appear identical between humans and 
animals, there may be differences, for example in specific 
receptors and enzymes, that will cause them to behave 
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very differently [54]. Non-human primates are often cited 
as having great genetic similarity with humans, but this 
belies the fact that in complex living systems even minor 
differences can result in significant differences in biologi-
cal processes and outcomes [55]. The case of TGN1412, 
which was tested in non-human primates precisely 
because of their close relation with humans, amply dem-
onstrates this. After just a few minutes of being infused 
with a dose 500 times smaller than that found safe in 
animal studies, all six human volunteers started suffer-
ing severe cytokine release syndrome leading to severe 
inflammation and multiple organ failure [56]. Wall and 
Shani [21] suggest that in some cases animal models can 
serve as a good analogue to study general principles, 
but not specific details. Details matter when it comes to 
developing safe and effective drugs for humans. As they 
write, ‘On average, the extrapolated results from stud-
ies using tens of millions of animals fail to accurately 
predict human responses.’ Consequently, they conclude 
that it is probably inadvisable to use animal models for 
extrapolation.
What can be done about the problem of species 
differences?
Transgenic mouse models were intended to enhance 
the external validity of animal models but as Geerts [9] 
suggests, if translation rates are anything to go by they 
have failed. This is because the paradigm suffers from 
the same problems; the SOD1 transgenic mouse, for 
example, appears to mimic humans in terms of some of 
the characteristics of motor neurone disease, but this 
is no guarantee that the same mechanisms are involved 
[10, 57]. Lynch [49] suggests that a way forward might 
be to empirically demonstrate (rather than assume) the 
similarity between animal and human genes with regard 
to the function being studied. Likewise, Seok et  al. [12] 
suggest that researchers should specify in advance the 
extent to which their animal model mimics the molecular 
behaviour of the key genes and key pathways thought to 
be important for the human disease under investigation. 
While this would appear to provide an answer however, it 
potentially leads us towards another problem of reason-
ing, namely the ‘extrapolator’s circle’. In other words, if 
we want to determine whether a mechanism in animals is 
sufficiently similar to the mechanism in humans to justify 
extrapolation, we must know how the relevant mecha-
nism in humans operates. But if we already know about 
the mechanism in humans then the initial animal study is 
likely to have been redundant [58] (depending upon the 
purpose of that animal study [59]).
Consequently we suggest that animal–human spe-
cies differences constitute a problem of external validity 
that cannot be overcome. Imagine that the next several 
decades are spent resolving the myriad problems of inter-
nal validity and the surmountable aspects of external 
validity (i.e. the representativeness of animal samples 
and the clinical relevance of animal models). While vast 
resources would be expended and colossal numbers of 
animals used and killed in this endeavour the end result 
would be only modest; the robustness of animal studies 
and the clinical relevance of animal models would likely 
improve to some extent. This unremarkable result would 
be due to the fact that despite improvements in animal 
models, the intractable issue of species differences would 
remain and would continue to make extrapolation from 
animals to humans unreliable. Along the way there might 
be some serendipitous findings but serendipity is not a 
reliable scientific method. Thus decades from now pre-
clinical animal studies would still fail to reliably and con-
sistently predict human responses and the findings from 
preclinical animal models would still fail to translate into 
benefits for humans. This is essentially the uninspiring 
scenario proposed by those who insist that the answer 
to the problem of translation lies in improving animal 
studies and animal models. This scenario is particularly 
unexciting given that current attempts to improve mat-
ters have so far failed [33, 60, 61].
An alternative approach, and one taken by an increas-
ing number of scientists, is to consider a paradigm for 
drug discovery that cuts out the uncertainty introduced 
by species differences [4, 6, 7, 62]. Within this paradigm 
new, human-relevant approaches and technologies are 
considered, such as the generation of human induced 
pluripotent stem cells (iPSC), which can be used to create 
disease- or patient-specific cell lines for testing potential 
drugs, micro-physiological systems known as ‘organs-
on-chips’, and human organoids (three dimensional cell 
cultures that incorporate key features of organs). Many of 
these new techniques integrate with in silico approaches 
and with systems biology, seen by many as having poten-
tial to revolutionise medicine [63, 64] and drug discovery 
[2]. Given that the return on investment for developing a 
new drug decreased from 10% in 2010 to 3% in 2017, the 
pharmaceutical industry certainly perceives a need to do 
things differently [5] and there is some considerable opti-
mism, both within industry [4, 6] and elsewhere, about 
the potential of these new approaches to increase the 
speed and accuracy of drug discovery. The US is making 
significant investments in organ-on-chip technologies [7] 
and the Netherlands is aiming to phase out animal use 
in the regulatory safety testing of medicines and chemi-
cals by 2025 [65] regarding new technologies as able to 
increase research relevance and deliver more reliable risk 
assessments whilst maintaining existing safety levels [66]. 
Systematic reviews are being used to review legacy data 
on drug safety [67] and this evidence, alongside low-risk 
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approaches such as microdosing in clinical trials [68], 
could provide a valuable safeguard during a transition to 
new technologies [69]. Systematic reviews will also have a 
role in synthesising emerging evidence about the efficacy 
of new technologies. Initial findings suggest that organs-
on-chips [70, 71] and in silico approaches [72] may have 
advantages over animal studies in terms of predicting 
adverse drug reactions. New physiologically relevant 
technologies also appear more capable of illuminating 
mechanisms of toxicity than animal studies [73–75].
Conclusion
We have argued that translation from animals to humans 
can only occur if preclinical animal studies are both 
internally and externally valid. We have also suggested 
that external validity consists of potentially modifi-
able features (e.g. representativeness of animal samples, 
clinical relevance of animal models) and unmodifi-
able features (animal–human species differences). Thus 
we suggest that while some aspects of animal models 
can be improved to a limited extent, they can never be 
fully externally valid because of the uncertainty intro-
duced by animal–human species differences. If the aim 
is to improve clinical translation and ultimately address 
patients’ needs for safe and effective treatments, the first 
step is to acknowledge where current systems are failing.
We noted that those conducting preclinical ani-
mal research appear to downplay the problem of ani-
mal–human species differences but interestingly, other 
researchers and commentators in the field do similarly. 
Although they may briefly acknowledge that species 
differences constitute a problem for external validity, 
the tendency is to focus on other, potentially modifi-
able, aspects of external validity [10, 26]. This is perhaps 
understandable, since acknowledging the issue of spe-
cies differences entails confronting the possibility that 
the preclinical animal research paradigm no longer has a 
great deal to offer. That possibility is alarming, not only to 
scientists who conduct animal research but also to those 
attempting to improve it. Yet there is a way forward. 
Research methods and technologies that are physiologi-
cally relevant to humans obviate the need for animals and 
thus eliminate the problem of animal–human species dif-
ferences. As a recent industry report [6] concluded, the 
time has come to humanise medicine. For the sake of 
patients and animals, we agree.
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